According to the COMPASS trial aspirin plus Xarelto improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease.
Resources
https://www.eurekalert.org/pub_releases/2017-08/esoc-rpa_1082617.php
https://www.nejm.org/doi/full/10.1056/NEJMoa1709118
https://www.acc.org/latest-in-cardiology/articles/2018/01/04/15/00/compass-trial
https://www.xarelto-us.com/